Cohen Yuval sold $171K of CRBP
Cohen Yuval (Chief Executive Officer) sold 17,000 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $10.08 ($0.17M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market sale details (shares, price, total value, and post-transaction holdings) executed under a 10b5-1 plan.
Market read
This is a routine insider-sale disclosure with limited fundamental implications due to the 10b5-1 plan.
What to watch
Traders may over-weight insider sales; without accompanying company-specific news (guidance, trial, financing), the filing is mostly informational.
Background
The article is a Form 4 insider transaction disclosure for Corbus Pharmaceuticals Holdings, Inc.
Ticker impact
Corbus CEO Cohen Yuval sold 17,000 shares in an open-market transaction at $10.0821 on 2026-08-07 under a 10b5-1 plan.
Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.
Form 4 provides a concrete transaction size, price, and post-sale holdings, but the pre-arranged 10b5-1 structure reduces interpretability as a new negative catalyst.
Market effects
No clear sector read-through from a single pre-arranged insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1 pre-arranged, it may reflect routine liquidity planning rather than bearish expectations.
Key entities
- issuerCorbus Pharmaceuticals Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderCohen Yuval
CEO and director who sold 17,000 shares.